Why Is Polar Capital Global Healthcare Trust Up Today?
Polar Capital Global Healthcare Trust plc shares rose 1.14% today to around 444.00p, as global healthcare equities staged a partial recovery after a period of relative underperformance against the broader market.
The move reflects a rebound in sentiment toward the healthcare sector, which has lagged more economically sensitive and AI-linked sectors for much of 2026 despite generally resilient fundamentals across pharmaceutical, biotechnology and medical technology companies.
Key Highlights
The trust's net asset value per share has fluctuated through 2026 in a range broadly between 370p and 420p, with recent factsheets showing NAV per share moving between roughly 379p and 414p depending on market conditions, alongside total net Assets in the region of £390–410 million.
Performance data shows the trust's ordinary shares delivering a 1-year total return of around 9–13%, with three-year total returns exceeding 20%, as measured against its benchmark, the MSCI ACWI/Healthcare NR GBP index, though healthcare has underperformed the broader global Equity market over shorter periods in 2026.
About Polar Capital Global Healthcare Trust
Polar Capital Global Healthcare Trust is a UK-listed Investment trust providing diversified exposure to global healthcare equities, managed by Gareth Powell and James Douglas, who have been recognised with Citywire ratings for their Risk-adjusted performance.
The trust's portfolio spans large-cap pharmaceutical companies, diagnostics and life-science tools businesses, and biotechnology names, with top holdings including Eli Lilly, Roche, AstraZeneca and Thermo Fisher Scientific, diversified by geography, sub-sector and company size.
Key Reasons Behind Today's Rally
Today's gain reflects a broader rotation back toward defensive and healthcare-linked equities after a period in which more economically sensitive sectors, supported by an improved geopolitical backdrop, and technology-linked sectors benefiting from continued AI enthusiasm, drove the bulk of global equity market returns.
Fund managers' commentary through 2026 has repeatedly noted that healthcare has 'materially underperformed the broader market' during periods when investor appetite favoured cyclical and AI-related themes, creating scope for a catch-up rally when sentiment rotates back toward the sector.
Portfolio Concentration in Large-Cap Pharma
The trust's largest holdings include Eli Lilly, at around 8% of the portfolio, alongside Roche, AstraZeneca, Thermo Fisher Scientific and Teva Pharmaceutical Industries, reflecting a strategy weighted toward established, cash-generative pharmaceutical and life-science tools companies rather than purely early-stage biotechnology names.
Geographically, the portfolio is weighted toward the United States, which represents around half of assets, with meaningful exposure to Switzerland, the United Kingdom, Denmark and other developed markets, providing a globally diversified approach to healthcare sector investing.
Structural Change and Tender Offers
The trust underwent a restructuring in 2017 that introduced regular tender offers, with shareholders subsequently voting in late 2025 to extend the company's life indefinitely subject to these periodic tender offers, providing a mechanism for shareholders to realise value at or close to NAV at set intervals.
This structure differentiates the trust from more permanent closed-ended vehicles, giving investors periodic Liquidity events while still allowing the manager to pursue a genuinely long-term investment approach across the healthcare sector.
Risks
As a healthcare-focused equity trust, PCGH's performance is closely tied to sentiment toward the sector as a whole, which can lag broader equity markets during periods when investors favour more cyclical or thematic areas such as artificial intelligence, as has been evident at points through 2026.
The trust employs gearing, which can amplify both gains and losses relative to the underlying portfolio, and its shares can trade at a premium or discount to NAV depending on market sentiment, meaning realised returns for shareholders can differ from the trust's underlying NAV performance.
Sector-specific risks include drug pricing policy changes, regulatory and Patent cliff risk for major pharmaceutical holdings, and clinical trial or regulatory setbacks affecting individual portfolio companies.
Valuation
PCGH's shares have traded at varying premiums and discounts to NAV through 2026, ranging from a small premium to a discount of around 3–4%, reflecting shifting sentiment toward the healthcare sector rather than any company-specific issue.
With healthcare having lagged the broader market for periods in 2026, some investors may see the sector, and by extension the trust, as offering relative value, particularly if economic or geopolitical conditions prompt a rotation back toward more defensive equity exposures.
What Investors Should Watch Next
Investors should monitor the trust's NAV performance relative to the MSCI ACWI/Healthcare benchmark, movements in its premium or discount to NAV, and broader sector rotation trends between defensive healthcare exposure and more cyclical or AI-linked equities.
Company-specific newsflow from top holdings such as Eli Lilly, Roche and AstraZeneca, including clinical trial results and drug pricing policy developments, will also be relevant to the trust's near-term performance.
Conclusion
Polar Capital Global Healthcare Trust's 1.14% gain today reflects a partial recovery in sentiment toward the global healthcare sector, which has underperformed more cyclical and AI-linked areas of the market for parts of 2026.
With a diversified portfolio of established pharmaceutical, diagnostics and life-science tools companies managed by an experienced, highly rated team, the trust offers investors broad exposure to the healthcare sector, with near-term returns likely to remain sensitive to shifts in relative sector sentiment.






Please wait processing your request...